Current practices for viability testing of cryopreserved cord blood products: an international survey by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative-Reference-Cited by-同舟云学术

Current practices for viability testing of cryopreserved cord blood products: an international survey by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative

Published:2018-09 Issue:9 Volume:58 Page:2184-2191
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Takanashi Minoko¹²,Selogie Eileen²,Reems Jo-Anna²³,Stroncek David²⁴,Fontaine Magali J.²⁵,Girdlestone John²⁶,Garritsen Henk S. P.²⁷⁸,Young Pampee²⁹,McKenna David H.²¹⁰,Szczepiorkowski Zbigniew M.²¹¹¹²,

Affiliation:

1. Japanese Red Cross Society Blood Service Headquarters; Tokyo Japan

2. Biomedical Excellence for Safer Transfusion (BEST) Collaborative; Dartmouth-Hitchcock Medical Center; Lebanon New Hampshire

3. University of Utah; Salt Lake City Utah

4. Department of Transfusion Medicine, Clinical Center; National Institutes of Health; Bethesda Maryland

5. Transfusion Services, Department of Pathology; University of Maryland School of Medicine; Baltimore Maryland

6. Stem Cells and Immunotherapies, NHS Blood and Transplant; The John Radcliffe Hospital; Oxford UK

7. Institute for Clinical Transfusion Medicine; Municipal Hospital Braunschweig gGmbH

8. Fraunhofer Institute for Surface Engineering and Thin Film IST; Braunschweig Germany

9. Vanderbilt University; Nashville Tennessee

10. Molecular & Cellular Therapeutics; University of Minnesota; Saint Paul Minnesota

11. Dartmouth-Hitchcock Medical Center; Lebanon New Hampshire

12. Institute of Hematology and Transfusion Medicine; Warsaw Poland

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.14777/fullpdf

Reference12 articles.

1. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM357135.pdf

2. Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples;Laroche;Transfusion,2005

3. Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysis;Saccardi;Transfusion,2016

4. Methods of freezing cord blood hematopoietic stem cells;Antoniewicz-Papis;Transfusion,2014

5. International standards for cord blood collection, banking, and release for administration [Internet] http://www.factwebsite.org/Standards/

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Criteria for storage of cord blood units at Japan's largest cord blood bank;Vox Sanguinis;2024-06-05

2. Cryopreserved hematopoietic stem/progenitor cells stability program-development, current status and recommendations: A brief report from the AABB-ISCT joint working group cellular therapy product stability project team;Cytotherapy;2022-05

3. Role of flow cytometry in evaluation of the cellular therapy products used in haematopoietic stem cell transplantation;International Journal of Laboratory Hematology;2022-04-13

4. Cryopreserved hematopoietic stem/progenitor cells stability program‐development, current status and recommendations: A brief report from the AABB‐ISCT joint working group cellular therapy product stability project team;Transfusion;2022-03

5. The wider perspective: cord blood banks and their future prospects;British Journal of Haematology;2021-04-20